TMCnet News
Cynata Executes MoU for Commercial Evaluation with Celularity, Inc.
MELBOURNE, Australia, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that the Company has entered into a memorandum of understanding (MoU) with Celularity, Inc., for the commercial evaluation of Cynata’s CymerusTM production technology for use with Celularity’s therapeutic stem cell technologies.
Celularity, Inc, is a leading US biotechnology company that uses its proprietary technology to harness cells from the postpartum placenta to address serious and life-threatening diseases, with strategic assets contributed from Celgene Corporation, Sorrento Therapeutics, United Therapeutics and Human Longevity, Inc.
Under the MoU, Cynata and Celularity have agreed to assess how Cynata’s technology can enhance Celularity’s ability to produce stem cells in large quantities. Cynata’s proprietary Cymerus platform will be evaluated in conjunction with Celularity’s cell therapy assets and the successful evaluation could lead to the development of new products and cell therapies in the regenerative medicine field. This MoU follows encouraging early clinical data in Cynata’s Phase 1 clinical trial of CYP-001 in acute steroid resistant GvHD, as announced to the ASX on 22 January 2018 and as partnered with Japanese corporation Fujifilm.
Celularity’s portfolio of innovative assets, developed from human placenta, includes cellular therapies to treat a broad range of degenerative and immunological diseases and cancer. Celularity’s immediate portfolio targets many debilitating human diseases, including acute myeloid leukemia, multiple myeloma, Crohn’s disease, diabetic peripheral neuropathy and diabetic foot ulcer, each affecting significant patient populations and representing multimillion dollar markets. Its portfolio also incorporates FDA-cleared biomaterial platforms that enable functional restoration of damaged and diseased tissues and organs. <>
Cynata’s unique Cymerus platform provides the ability to produce mesenchymal stem cells (MSCs) at scale, making it the ideal solution to solve the inherent scalability challenge with stem cell therapies. Furthermore, the platform is agnostic, giving it broad therapeutic application across a range of diseases.
Celularity, Inc. was created through a deliberate combination of synergistic cellular medicine assets of leading cellular and genomic technology companies – Celgene Cellular Therapeutics (CCT), United Therapeutics, Sorrento Therapeutics, Inc., and Human Longevity, Inc. With these consolidated assets, Celularity combines cellular therapeutics, regenerative medicine technology and a proven placental biosourcing infrastructure. At the core is an effective platform to discover, innovate and deliver therapeutic products and services for treating life threatening diseases and for providing future disruptive advances uniquely suited to operate in the emerging precision medicine environment.
Celularity’s placental-based technology was pioneered by Dr. Robert Hariri, who discovered placental pluripotent stem cells and invented the first placental amniotic membrane product for wound care more than 15 years ago and has since expanded the use of placental cells to numerous other indications and commercial products. In addition to Dr. Hariri, who is Celularity’s founder, CEO and Chairman, Celularity’s leadership team has significant expertise and decades of experience working within the biotechnology sector. Vice-Chairman Dr. Peter Diamandis is the Founder and Executive Chairman of XPRIZE and Singularity University, a graduate-level Silicon Valley institution that studies exponentially growing technologies.
Dr. Ross Macdonald, CEO, Cynata Therapeutics commented: “Celularity’s US-focused team is the perfect partner to explore our unique Cymerus technology. We continue to seek new commercial opportunities for our Cymerus platform and this agreement builds on our existing strategic partnership with Fujifilm and represents a unique opportunity to expand our disease target areas into a number of significant markets, including the US.”
Dr. Robert Hariri, Founder, Chairman and CEO of Celularity, Inc. commented: “The value in the Cymerus platform is its unique ability to produce therapeutic grade mesenchymal stem cells at scale. Our stem cell therapies would immensely benefit from mass production and it is for this reason we have chosen to enter into a MoU with Cynata. A cooperation between our two companies has the potential to lead to any number of new commercial opportunities and I look forward to working alongside Cynata to explore the opportunities available to us.”
About Cynata Therapeutics (ASX:CYP)
About Celularity, Inc. 1 Research and Markets - Global Regenerative Medicine Market Analysis & Forecast
|